Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
MaxCyte Inc on Wednesday reported a jump in its first quarter revenue, which it said was driven by its core business sales.
Shares in MaxCyte were up 9.5% at 317.50 pence each in London on Wednesday morning.
MaxCyte is a Rockville, Maryland-based provider of cell engineering platform technologies developing ‘next-generation cell therapeutics’.
In the three months to March 31, revenue jumped 32% to $11.3 million from $8.6 million the year before.
This was largely driven by core business revenue, which stood at $8.2 million, up 14% from $7.2 million in the first quarter of 2023.
Net loss narrowed to $9.5 million from $10,9 million a year prior, while loss before interest, tax, depreciation and amortisation narrowed to $11.2 million from $12.2 million a year ago.
Looking ahead, MaxCyte said that it continues to expect full-year core business revenue growth of between 0% to 5%.
It also expects to end 2024 with at least $175 million in total cash, cash equivalents and investments.
Copyright 2024 Alliance News Ltd. All Rights Reserved.